Shire Plc (SHPG)

179.20
7.05 4.10
Prev Close 172.15
Open 176.60
Day Low/High 175.71 / 181.22
52 Wk Low/High 123.73 / 182.47
Volume 5.32M
Avg Volume 1.63M
Exchange
Shares Outstanding 300.99M
Market Cap 54.82B
EPS 14.30
Div & Yield 1.06 (0.59%)
Closing Bell: HP Inc. Up on Hewlett-Packard Split; Stocks Rally

Closing Bell: HP Inc. Up on Hewlett-Packard Split; Stocks Rally

U.S. markets ended Monday's session in the green as deal news boosted the health care sector following Shire's announcement that it would acquire drugmaker Dyax.

Finding Value Amid Mindless ETF-ization

This is what matters in making more money for your portfolio.

Midday Report: Dyax Deal Boosts Health Care; Stocks Climb

Midday Report: Dyax Deal Boosts Health Care; Stocks Climb

Stocks started November on strong footing, extending October's stellar run.

Day Ahead: Weak ADP Cheers Markets

Day Ahead: Weak ADP Cheers Markets

Futures jump on hopes for a later Fed rate hike.

Quant Picks: 4 Pharmaceutical Companies to Add to Your Porfolio

Quant Picks: 4 Pharmaceutical Companies to Add to Your Porfolio

Here are some of the best pharmaceuticals our algorithm says you should consider looking at.

Baxalta Shares Spike Following Shire's $30.6B Takeover Offer

Baxalta Shares Spike Following Shire's $30.6B Takeover Offer

Drug manufacturer Baxalta (BXLT) was the best performing stock in the S&P 500 Tuesday after an unsolicited takeover offer from a competitor. The stock is TheStreet's Move of the Day.

Baxalta Rejects Shire Offer; Stocks Slip in Volatile Session

Baxalta Rejects Shire Offer; Stocks Slip in Volatile Session

Baxalta (BXLT) shares were on watch after the company rejected an unsolicited offer from Shire (SHPG).

Shire Proposes $30B Deal to Buy Disease Specialist Baxalta

Shire Proposes $30B Deal to Buy Disease Specialist Baxalta

Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.

Sometimes, Breaking Up Is Smart to Do

Sometimes, Breaking Up Is Smart to Do

A company that divides itself can unlock value.

Day Ahead: Greece Returns

Day Ahead: Greece Returns

The rhetoric is becoming divisive again.

There Are Still a Few Bargains Around

There Are Still a Few Bargains Around

They're in the tech, pharma and biotechnology sectors.

A Tasty Reversal With 6 Key Ingredients

But tomorrow we hear from the banks.

Avoid the Crowd

There is virtually no room for error in a crowded trade.

Boxes: Checked!

Boxes: Checked!

We now have an investable bottom on our hands.

We Aren't Done Yet

There will likely be more selling until the elusive bottom is reached.

This Morning's Market Setup

Where it began. "As I mentioned earlier, the divergences seen since late summer are starting to weigh on stocks:  "Underperformance of the Russell Index. "Weakening in the cumulative advance/decline line of the Nasdaq. "Contraction in the number of ...

Futures Mixed in Reaction to Int'l Headlines; AbbVie, Shire Deal

Futures Mixed in Reaction to Int'l Headlines; AbbVie, Shire Deal

The futures markets are mixed this morning as news of the Malaysian Airlines plane shot down in the Ukraine and tensions in Gaza dominate investors minds.

Shire Deal Just The Start

Shire Deal Just The Start

Shire's purchase of ViroPharma is a signal of deals and higher prices ahead, says Jason Kolbert, Sr. Research Analyst at the Maxim Group.

Rules of the Game: Healthy Fundamentals

Rules of the Game: Healthy Fundamentals

These three medical stocks are moving up in heavier-than-normal volume.